Latest Definium Therapeutics News & Updates

See the latest news and media coverage for Definium Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Definium Therapeutics

Psychedelic medicine company for brain health disorders

definiumtx.com
Headquarters
New York, United States
Founded year
2019
Company type
Public company
Number of employees
150–200
Industry
Pharmaceuticals

Last updated

Latest news about Definium Therapeutics

In short: Definium Therapeutics reported positive Phase 3 results for its LSD-based therapy DT120 in depression and anxiety and raised $805 million.

Company announcements

Definium Therapeutics

Definium Therapeutics reports Phase 3 results for LSD in MDD

CEO Robert Barrow discusses positive Emerge results and the company's commitment to advancing mental health treatments

Unlock all announcements with a

Media coverage

Psychiatric Times

DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial | Psychiatric Times

DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single...

Unlock all articles with a

Never miss news about Definium Therapeutics

Track Definium Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.